SignalFDA/Bio

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Phase III Tam-Peli data show significantly improved overall survival in relapsed small-cell lung cancer.

What changed

Phase III Tam-Peli data show significantly improved overall survival in relapsed small-cell lung cancer.

Why it matters

Phase III Tam-Peli data show significantly improved overall survival in relapsed small-cell lung cancer. — impact context not separately stored; see What changed.

Sources

eodhd